Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis.
Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis.
复制标题
DOI：
10.1371/journal.pone.0029492
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
García-Vicuña R
中科院分区：
文献类型：
--
作者：
González-Álvaro I;Ortiz AM;Alvaro-Gracia JM;Castañeda S;Díaz-Sánchez B;Carvajal I;García-Vadillo JA;Humbría A;López-Bote JP;Patiño E;Tomero EG;Vicente EF;Sabando P;García-Vicuña R
白细胞介素-15（IL-15）被认为参与RA的生理病理机制，并且它可以在RA患者的血清和炎症关节的滑液中检测到，但在骨关节炎或其他炎性关节疾病患者中检测不到。因此，这项工作的目的是分析是否血清IL-15（sIL-15）水平作为早期关节炎（EA）患者的疾病严重程度的生物标志物。分析了190例EA登记患者的数据（77.2%为女性;中位年龄53岁;入组时中位病程6个月）。系统地记录临床和治疗信息，特别是改善疾病的抗风湿药物处方。使用不同的因变量进行了两项多变量纵向分析：1）DAS 28和2）反映强化治疗的变量。两者均包括sIL-15作为预测变量和与疾病严重程度相关的其他变量，包括类风湿因子（RF）和抗环瓜氨酸肽抗体（ACPA）。在完成随访的171例患者（分析了638次访视）中，71%患有类风湿性关节炎，29%被认为是未分化关节炎。在该人群中检测到29%的sIL-15升高，该生物标志物与RF或ACPA没有广泛重叠。在调整性别、年龄和治疗等混杂变量后，高sIL-15水平（β系数[95%置信区间]：0.12 [0.06-0.18]; p<0.001）或ACPA（0.34 [0.01-0.67]; p =0.044）与随访期间较高的DAS 28显著独立相关。 此外，sIL-15升高的患者接受强化治疗的风险显著更高（RR 1.78，95%置信区间1.18-2.7; p = 0.007）。 显示高基线sIL-15的EA患者患有更严重的疾病并接受更强化的治疗。因此，sIL-15可能是早期和更密集治疗的候选患者的生物标志物。
Interleukin-15 (IL-15) is thought to be involved in the physiopathological mechanisms of RA and it can be detected in the serum and the synovial fluid of inflamed joints in patients with RA but not in patients with osteoarthritis or other inflammatory joint diseases. Therefore, the objective of this work is to analyse whether serum IL-15 (sIL-15) levels serve as a biomarker of disease severity in patients with early arthritis (EA). Data from 190 patients in an EA register were analysed (77.2% female; median age 53 years; 6-month median disease duration at entry). Clinical and treatment information was recorded systematically, especially the prescription of disease modifying anti-rheumatic drugs. Two multivariate longitudinal analyses were performed with different dependent variables: 1) DAS28 and 2) a variable reflecting intensive treatment. Both included sIL-15 as predictive variable and other variables associated with disease severity, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (ACPA). Of the 171 patients (638 visits analysed) completing the follow-up, 71% suffered rheumatoid arthritis and 29% were considered as undifferentiated arthritis. Elevated sIL-15 was detected in 29% of this population and this biomarker did not overlap extensively with RF or ACPA. High sIL-15 levels (β Coefficient [95% confidence interval]: 0.12 [0.06–0.18]; p<0.001) or ACPA (0.34 [0.01–0.67]; p = 0.044) were significantly and independently associated with a higher DAS28 during follow-up, after adjusting for confounding variables such as gender, age and treatment. In addition, those patients with elevated sIL-15 had a significantly higher risk of receiving intensive treatment (RR 1.78, 95% confidence interval 1.18–2.7; p = 0.007). Patients with EA displaying high baseline sIL-15 suffered a more severe disease and received more intensive treatment. Thus, sIL-15 may be a biomarker for patients that are candidates for early and more intensive treatment.
登录
查看更多内容
影响因子：
27.4
作者：
González-Alvaro I;Ortiz AM;Domínguez-Jiménez C;Aragón-Bodi A;Díaz Sánchez B;Sánchez-Madrid F
通讯作者：
Sánchez-Madrid F
影响因子：
82.9
作者：
McInnes, IB;Leung, BP;Liew, FY
通讯作者：
Liew, FY
影响因子：
4.9
作者：
Ibañez M;Ortiz AM;Castrejón I;García-Vadillo JA;Carvajal I;Castañeda S;González-Alvaro I
通讯作者：
González-Alvaro I
影响因子：
4.4
作者：
Miranda-Carús, ME;Balsa, A;Martín-Mola, E
通讯作者：
Martín-Mola, E
影响因子：
82.9
作者：
McInnes, IB;AlMughales, J;Liew, FY
通讯作者：
Liew, FY